Product Description
For Cancer Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Auron Healthcare
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Colorectal Cancer|Gastrointestinal Cancer|Genital Cancer, Female|Prostate Cancer
Phase 2: Hepatocellular Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| AMT/P2GI/001 Part I | P2 |
Terminated |
Hepatocellular Carcinoma |
2010-03-01 |
|
| AMT/P2GI/001 Part III | P3 |
Terminated |
Colorectal Cancer |
2010-01-01 |
|
| AMT/P2CA/001 | P3 |
Terminated |
Genital Cancer, Female|Gastrointestinal Cancer|Prostate Cancer |
2010-01-01 |